Skip to main content
. 2023 Feb 17;12(13):2202590. doi: 10.1002/adhm.202202590

Figure 1.

Figure 1

Schematic illustration of YK009‐LNP‐Omicron mRNA vaccine against SARS‐CoV‐2 Omicron variant. A) YK009‐LNP‐Omicron mRNA was prepared by mixing liposoluble alkaline lipids and mRNA acid aqueous solution through a microfluidic system. B) Mice were immunized via intramuscular (i.m.) administration with YK009‐LNP‐Omicron mRNA vaccines. YK009‐LNP‐Omicron mRNA vaccines induce neutralizing antibody and T cell response in mice. C) YK009‐LNP‐Omicron mRNA vaccines provide protection against SARS‐CoV‐2 Omicron variant.